POEMS Syndrome and Disease Produced by Other Monoclonal Immunoglobulins

82

Gordon Cook and Montserrat Rovira

82.1 POEMS Syndrome

82.1.1 Introduction

POEMS syndrome (acronym of *polyradiculoneuropathy, organomegaly, endocrinopathies, monoclonal protein, and dermopathy, skin*) is a rare multisystemic disease due to an underlying plasma cell neoplasm. The pathogenesis of the syndrome is not well understood. Other names of the POEMS syndrome that are less frequently used are osteosclerotic myeloma, Takatsuki syndrome, or Crow-Fukase syndrome.

82.1.2 Clinical and Laboratory Manifestations

POEMS predominate in male being the age of maximum incidence (50–60 years).

Characteristic manifestations are:

Polyneuropathy: Typically demyelinating. Peripheral, ascending, symmetrical and affecting both sensation and motor function. It is the dominant characteristic.
Organomegaly: Hepatomegaly (50%), splenomegaly, or lymphadenopathy.
Endocrinopathy: Present in 84% of patients: gonadal, thyroid, pituitary, parathyroid, pancreatic, adrenal (in order of frequency, and many times multiple).
Monoclonal protein: Almost always λ light chain. Usually Ig A or IgG and ≤ 3 g/dL. Bone marrow smear < 5 to 10% plasma cells.
Skin changes: Hyperpigmentation, hypertrichosis, glomeruloid hemangiomas, white nails, plethora, acrocyanosis, flushing.
Other important manifestations are: <ul style="list-style-type: none"> — Papilledema (in one third of patients) — Extravascular volume overload — Sclerotic bone lesions^a (95%) — Thrombocytosis (in 54%) — VEGF elevation^b — Castleman disease (in 11–30%)

^aRadiology and CT/PET can be useful

^bVEGF = Vascular endothelial growth factor is the cytokine that correlates best with disease activity. The helpful cutoff for plasma and serum VEGF levels for diagnosis are > 200 pg/mL (specificity 95%, sensitivity 68%) and > 1920 pg/mL (specificity 98%, sensibility 73%), respectively

G. Cook
Haematology and Myeloma Studies, Leeds Cancer Centre, St James's University Hospital, Leeds, UK

M. Rovira (✉)
Hematology Department, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Catalunya, Spain
e-mail: mrovira@clinic.cat

82.1.3 Diagnosis

Not all the features within the acronym are required to make the diagnosis. There are other relevant features not included in the POEMS acronym also important: PEST

Table 82.1 Criteria for the diagnosis of POEMS syndrome

The diagnosis of POEMS syndrome is confirmed when:	
— Both mandatory major criteria +	
— Another of the other three major criteria +	
— At least one of the minor criteria	
Mandatory major criteria	Other major criteria
Polyneuropathy	Castleman disease
Monoclonal immunoglobulin	Sclerotic bone lesions
	VEGF elevated
Minor criteria	Other symptoms and signs
Organomegaly (splenomegaly, hepatomegaly, or lymphadenopathy)	Digital clubbing
	Weight loss
	Hyperhidrosis
Extravascular volume overload (edema, pleural effusion, or ascites)	Low vitamin B12 values
	Diarrhea
Endocrinopathy ^a	Pulmonary hypertension/restrictive lung disease
Skin changes	
Papilledema	Thrombosis
Thrombocytosis/erythrocytosis ^b	

Adapted from Dispenzieri (2017)

^aHypogonadism is the most frequent, and because of the high prevalence of diabetes mellitus and thyroid abnormalities, these two last abnormalities alone are not sufficient to meet this minor criterion

^bAnemia and/or thrombocytopenia are rare, unless associated with Castleman disease

(papilledema, extravascular volume overload, sclerotic bone lesions, thrombocytosis/erythrocytosis), elevated VEGF levels, abnormal pulmonary function tests, and a predisposition to thrombosis.

There is a Castleman variant of POEMS syndrome that may be associated with a clonal plasma cell disorder. When Castleman disease variant of POEMS syndrome occurs without evidence of plasma cell disorder, then this entity should be considered separately.

Clinical criteria for POEMS diagnostic are shown in Table 82.1.

82.1.4 Prognosis

Chronic course, median survival of nearly 14 years, rarely progression to multiple myeloma.

The number of POEMS features does not affect survival.

Risk factors associated to better survival are: albumin >3.2 g/dL, achievement of a complete hematological response and younger age. Lower VEGF levels, better response to treatment.

Risk factors associated to shorter survival are: clubbing, extravascular volume overload, respiratory symptoms, papilledema, and coexisting Castleman disease.

Thrombocytosis and high bone marrow infiltration are associated with risk of cerebrovascular accidents.

Patients candidates for radiation therapy have a better overall survival.

82.1.5 Standard Treatment

82.1.5.1 In Case of an Isolated Bone Lesion (or Multiple, But Localized)

Radiotherapy to affected site(s) improves the symptoms of POEMS syndrome and can be curative.

82.1.5.2 Rest of Patients (Disseminated Disease)

- MEL/DEX
- LENA/DEX, THAL/DEX, BOR (these last two agents are of limited use due to the intrinsic risk of peripheral neuropathy), CY/DEX.

- Plasmapheresis, IVIg, IFN- α , tamoxifen, ATRA, bevacizumab (anti-VEGF agent), argatroban, and strontium-89 (mostly single-case reports).
- Attention to supportive care is mandatory (physical therapy, orthotics, etc.).
- Auto-HSCT.

82.1.5.3 Response Criteria

Monitoring the response to treatment in POEMS syndrome is a challenge. Patients must be followed carefully comparing the deficits to baseline. VEGF is an imperfect marker due to discordances between disease activity and response. The size of monoclonal protein is typically small making standard MM response criteria inapplicable. Patients can present clinical benefit without M-protein response therefore a clinical scoring system which can focus on organ-specific response would be useful clinically. So, response criteria for POEMS syndrome could be done as follows: hematological response using a modified amyloid response criteria, VEGF response, CT/PET response, and a simplified organ response (polyneuropathy assessment, pulmonary function tests, and extravascular overload).

82.1.6 Autologous HSCT (Table 82.2)

82.2 Monoclonal Ig Deposition Disease

82.2.1 Introduction

Monoclonal Ig deposition is a clonal plasma cell dyscrasia in which light-chain and/or heavy-chain subunits of Igs form non-fibrillar deposits in various tissues, causing organ dysfunction. Light-chain deposition disease is the most common of these entities.

Table 82.2 Main characteristic of auto-HSCT for POEMS disease treatment

Background	<ul style="list-style-type: none">— In MM, another gammopathy, auto-HSCT, has a high rate of responses— In amyloidosis, a disease with similarities to POEMS syndrome with “low tumor” burden, auto-HSCT offers encouraging results
Indication	<p>POEMS syndrome with disseminated disease and:</p> <ul style="list-style-type: none">— Good general condition— Without response to standard treatment (MEL + DEX 2–3 months)— With high-risk factors (?)
Conditioning	MEL 140–200 mg/m ^{2a}
Stem cell source	PBSC, mobilization with G-CSF $\pm$ CY (3 g/m ²) ^{b,c}
Morbidity	<ul style="list-style-type: none">— High rate of engraftment syndrome (up to 50%) (see Chap. 42), important to recognize and treat promptly with PRD. In these cases, higher than expected transfusion need and delayed engraftment— No organ toxicities as observed in amyloidosis
Mortality	As in other auto-HSCT, recently reported 3.3% at 1-year NRM ^d
Response ^{d,e}	Usually delayed, from 6 months post-auto-HSCT to 24–72 months

^aWith lower dose, inferior responses
^bMobilization failure is described, for this reason if there is no response after three courses of MEL + DEX, proceed to mobilization
^cThe incidence of engraftment syndrome can be reduced if mobilization is done with CY + G-CSF
^dCook et al. (2017)
^eIn the largest series, 3-year PFS 84% and OS 94%, and 5-year PFS 74% and OS 89%

82.2.2 Clinical Manifestation/
Laboratory

<i>Kidney</i>
<ul style="list-style-type: none">— Always affected: nephrotic syndrome, hypertension, and rapidly progressing renal insufficiency— Immunofluorescence shows deposition of light chains along glomerular and tubular basement membranes $\rightarrow$ nodular glomerulosclerosis— Deposits are non-fibrillar, almost always composed of κ chain, and do not stain with Congo red dye
<i>Heart and liver</i>
<ul style="list-style-type: none">— Less frequently affected: restrictive cardiopathy, myocardial infarction, cholestatic jaundice, hepatic failure
<i>Monoclonal gammopathy</i>
<ul style="list-style-type: none">— Electrophoresis, immunofixation of serum and/or urine, serum-free light chain measurement

Table 82.3 Main characteristic of auto-HSCT for monoclonal Ig deposition disease treatment

Background	— As in POEMS syndrome (see Table 82.2)
Indication	— Patients in good general condition and with basic requirements for auto-HSCT — Patients not responding to previous MM-like treatment
Conditioning	Melphalan 140–200 mg/m ²
Stem cell source	PB, mobilization with G-CSF ± CY (3 g/m ²)
Morbidity	Some patients require hemodialysis (HD) before and during the procedure. In that case, MEL should be administered after HD
Mortality	As in other auto-HSCT
Response	In the few cases reported: — Hematological responses are described secondary to the control of the monoclonal gammopathy — It can improve renal function. In selected cases, kidney transplantation could be an option if the patient achieves a CR and remain in HD

82.2.3 Diagnosis

Based on the biopsy of the affected organ (almost always kidney)

82.2.4 Treatment

Controversial, not standard due to the low incidence. Conventional chemotherapy commonly used for MM is unsatisfactory. Possible alternatives are:

- MEL + prednisone
- VAD (vincristine, doxorubicin, DEX)
- THAL/DEX, BOR/DEX
- Auto-HSCT (see Table 82.3)

Recommended References

Batalini F, Econimo L, Quillen K, et al. High-dose melphalan and stem cell transplantation in patients on dialysis due to immunoglobulin light-chain amyloidosis and monoclonal immunoglobulin deposition disease. *Biol Blood Marrow Transplant*. 2018;24:127–32.

Cook G, Iacobelli S, Van Biezen A, et al. High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Chronic Mailnancy Working Party of the European Society for Blood and Marrow Transplantation. *Haematologica*. 2017;102:160–7.

D’Souza A, Lacy M, Gertz M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome: a single-center experience. *Blood*. 2012;120:56–62.

Dispenzieri A. POEMS syndrome: 2017 update on diagnosis, risk-stratification, and management. *Am J Hematol*. 2017;92:814–29.

Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. *Blood*. 2003;101:2496–506.

Dispenzieri A, Lacy MQ, Hayman SR, et al. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. *Eur J Haematol*. 2008;80:397–406.

Girnius S, Seldin DC, Quillen K, et al. Long-term outcome of patients with monoclonal IgG deposition disease treated with high-dose melphalan and stem cell transplantation. *Bone Marrow Transplant*. 2011;46:161–2.

Hassoun H, Flombaum C, D’Agati VD, et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. *Bone Marrow Transplant*. 2008;42:1–8.

Jaccard A, Royer B, Bordessoule D, et al. High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome. *Blood*. 2002;99:3057–9.

Kourelis TV, Buadi FK, Kumar SK, et al. Long-term outcome of patients with POEMS syndrome: an update of the Mayo Clinic experience. *Am J Hematol*. 2016;91:585–9.

Li J, Zhang W, Jiao L, et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. *Blood*. 2011a;117:6445–9.

Li J, Zhou DB, Huang Z, et al. Clinical characteristics and long-term outcome of patients with POEMS syndrome in China. *Ann Hematol*. 2011b;90:819–26.

Pozzi C, D’Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. *Am J Kidney Dis*. 2003;42:1154–63.

Rovira M, Carreras E, Blade J, et al. Dramatic improvement of POEMS syndrome following autologous haematopoietic cell transplantation. *Br J Haematol*. 2001;115:373–5.

Tovar N, Cibeira MT, Rosiñol L, et al. Bortezomib/dexamethasone followed by stem cell transplantation as front line treatment for light-chain deposition disease. *Eur J Haematol*. 2012;89(4):340–4.

Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.